{"id":58,"date":"2021-03-19T10:44:17","date_gmt":"2021-03-19T14:44:17","guid":{"rendered":"https:\/\/prastera.com\/?page_id=58"},"modified":"2021-04-21T09:43:57","modified_gmt":"2021-04-21T13:43:57","slug":"breast-cancer","status":"publish","type":"page","link":"https:\/\/prastera.com\/?page_id=58","title":{"rendered":"Breast Cancer"},"content":{"rendered":"\n<p class=\"has-drop-cap has-pale-cyan-blue-background-color has-background\">In the placebo-controlled clinical trials, the prasterone treated group had a significantly lower incidence of breast cancer than the placebo group.&nbsp; Among subjects at least 45 years of age, incidence of breast cancer in the placebo group was 4.2%, and 1.5% in prasterone-treated group (p = 0.018).&nbsp; Expressed as a rate per patient-year of observation for patients &gt;45 years of age, these rates are 4.6\/1000 for prasterone and 6.5\/1000 for placebo. &nbsp;However, it would appear prudent for post-menopausal patients receiving Prastera<sup>\u00ae<\/sup> to follow current mammography guidelines.&nbsp;<\/p>\n\n\n\n<p>In the Phase 3 clinical trials, the treatment and placebo groups showed no difference in meno-metrorrhagia or vaginal bleeding, and post-menopausal patients showed no difference in endometrial hyperplasia (as measured by uterine ultrasound screening and uterine biopsies). &nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><img loading=\"lazy\" width=\"702\" height=\"563\" src=\"https:\/\/prastera.com\/wp-content\/uploads\/2021\/03\/Breast-Cancer-incidence.jpg\" alt=\"\" class=\"wp-image-29\" srcset=\"https:\/\/prastera.com\/wp-content\/uploads\/2021\/03\/Breast-Cancer-incidence.jpg 702w, https:\/\/prastera.com\/wp-content\/uploads\/2021\/03\/Breast-Cancer-incidence-300x241.jpg 300w\" sizes=\"(max-width: 702px) 100vw, 702px\" \/><\/figure><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In the placebo-controlled clinical trials, the prasterone treated group had a significantly lower incidence of breast cancer than the placebo group.&nbsp; Among subjects at least 45 years of age, incidence of breast cancer in the placebo group was 4.2%, and 1.5% in prasterone-treated group (p = 0.018).&nbsp; Expressed as a rate per patient-year of observation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/prastera.com\/?page_id=58\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":284,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/pages\/58"}],"collection":[{"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prastera.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58"}],"version-history":[{"count":3,"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/pages\/58\/revisions"}],"predecessor-version":[{"id":65,"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/pages\/58\/revisions\/65"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prastera.com\/index.php?rest_route=\/wp\/v2\/media\/284"}],"wp:attachment":[{"href":"https:\/\/prastera.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}